Clinical Trial Update: A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing YL201 to investigator's choice chemotherapy in locally advanced or metastatic esophageal squamous cell carcinoma after failure …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Investigator's Choice of Chemotherapy
• YL201

Snippet

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. | Conditions: Advanced Esophageal Squamous Cell Carcinoma | Phase 3 | Status: NOT_YET_RECRUITING